Ondansetron: Rosacea

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@kumc.edu.

Get full access to this article

View all access options for this article.

References

Yamasaki

Di Nardo

Bardan

Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13(8): 975–980.

van Zuuren

E.J.

Gupta

A.K.

Cover

M.D.

Graber

Hollis

Systematic review of rosacea treatments. J Am Acad Dermatol. 2007; 56(1): 107–115.

Wilkin

Dahl

Detmar

Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002; 46(4): 584–587.

Wollina

The response of erythematous rosacea to ondansetron. Br J Dermatol. 1999; 140(3): 561–562.

Del Rosso

J.Q.

Baldwin

Webster

; American Acne Rosacea Society. American Acne and Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008; 7(6): 531–533.

Elewski

B.E.

Draelos

Dréno

Jansen

Layton

Picardo

Rosacea—global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011; 25(2): 188–200.